(Applicant's Description) The University of Pittsburgh Cancer Institute (UPCI) is a multidisciplinary cancer research center, with programs in basic research, translational research and clinical investigations, prevention and control, early diagnosis and treatment, and behavioral medicine research. In addition, it has responsibility of cancer education and clinical care. The UPCI is comprised of faculty form the University of Pittsburgh and Carnegie Mellon University and utilizes the clinical facilities of the University of Pittsburgh and Medical Center Health System plus two University affiliated hospitals (Children's Hospital of Pittsburgh and Magee Women's Hospital). The UPCI has established programs in: molecular and cellular oncology, molecular therapeutic and drug discovery, immunology, molecular virology, lung cancer, prostate and urologic cancers, head and neck cancer, biological therapeutics, cancer epidemiology, prevention and control, and behavioral medicine and oncology. To assist its research efforts, the UPCI maintains shared facilities including: Biostatistics Facility, Clinical Research Support Services, Immunologic Monitoring Laboratory, Cellular Products Laboratory, Hybridoma Facility, Flow Cytometry Facility, DNA Sequencing Facility, Peptide Synthesis Facility, Animal Facility, Glassware Facility, Oligonucleotide Facility, and Cell and Tissue Imaging Facility. This application requests continued cancer center support grant (CCSG) funding for the University of Pittsburgh Cancer Institute's program for years 12-16.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-14
Application #
6375813
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1988-08-01
Project End
2004-07-30
Budget Start
2001-08-01
Budget End
2002-07-31
Support Year
14
Fiscal Year
2001
Total Cost
$3,880,685
Indirect Cost
Name
University of Pittsburgh
Department
Pathology
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Chen, Ruochan; Zhu, Shan; Fan, Xue-Gong et al. (2018) High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology 67:1823-1841
Zahorchak, Alan F; Macedo, Camila; Hamm, David E et al. (2018) High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. Cell Immunol 323:9-18
Rogers, Meredith C; Lamens, Kristina D; Shafagati, Nazly et al. (2018) CD4+ Regulatory T Cells Exert Differential Functions during Early and Late Stages of the Immune Response to Respiratory Viruses. J Immunol 201:1253-1266
Jing, Y; Nguyen, M M; Wang, D et al. (2018) DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor. Oncogene 37:638-650
Singh, Krishna B; Ji, Xinhua; Singh, Shivendra V (2018) Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer. Mol Cancer Ther 17:2079-2090
Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15
Gao, Ying; Tan, Jun; Jin, Jingyi et al. (2018) SIRT6 facilitates directional telomere movement upon oxidative damage. Sci Rep 8:5407
Krishnamurthy, Anuradha; Dasari, Arvind; Noonan, Anne M et al. (2018) Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res 78:5398-5407
Santos, Patricia M; Butterfield, Lisa H (2018) Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology 155:1684-1686
Liu, Zuqiang; Ge, Yan; Wang, Haiyan et al. (2018) Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. Nat Commun 9:4682

Showing the most recent 10 out of 1187 publications